Edwards Lifesciences Corp
NYSE:EW
Intrinsic Value
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. [ Read More ]
The intrinsic value of one EW stock under the Base Case scenario is 62.27 USD. Compared to the current market price of 95.56 USD, Edwards Lifesciences Corp is Overvalued by 35%.
Valuation Backtest
Edwards Lifesciences Corp
Run backtest to discover the historical profit from buying and selling EW stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Company Aims to Boost Full-Year TMTT Sales
2023-Q4 Earnings Call
The company expressed optimism with forecasts, expecting full-year TMTT sales to hit the higher end of the $280 million - $320 million guidance. For Q1, anticipated sales are between $1.53 billion and $1.61 billion, with adjusted EPS of $0.62 to $0.66. Margins dipped to 76.8% versus last year's 81% due to exchange rate impacts, but the adjusted gross profit margin is anticipated to stabilize between 76% and 78% in 2024. Investments in transcatheter personnel and patient activation initiatives increased SG&A to $480 million (31.3% of sales), targeting 29-30% for the full year. R&D spending rose by 16% to $270 million, aiming for 17-18% of 2024 sales. Free cash flow for Q4 was $48 million, with adjusted free cash flow in 2023 at $943 million, excluding a $300 million payment. For 2024, free cash flow is projected to grow between $1.1 billion and $1.4 billion.
Balance Sheet Decomposition
Edwards Lifesciences Corp
Current Assets | 4B |
Cash & Short-Term Investments | 1.6B |
Receivables | 836.9m |
Other Current Assets | 1.6B |
Non-Current Assets | 5.3B |
Long-Term Investments | 583.9m |
PP&E | 1.8B |
Intangibles | 1.7B |
Other Non-Current Assets | 1.2B |
Current Liabilities | 1.2B |
Accounts Payable | 1.4B |
Accrued Liabilities | 819.7m |
Other Current Liabilities | -996.2m |
Non-Current Liabilities | 1.5B |
Long-Term Debt | 597m |
Other Non-Current Liabilities | 920.8m |
Earnings Waterfall
Edwards Lifesciences Corp
Revenue
|
6B
USD
|
Cost of Revenue
|
-1.4B
USD
|
Gross Profit
|
4.6B
USD
|
Operating Expenses
|
-2.9B
USD
|
Operating Income
|
1.8B
USD
|
Other Expenses
|
-352.4m
USD
|
Net Income
|
1.4B
USD
|
Free Cash Flow Analysis
Edwards Lifesciences Corp
What is Free Cash Flow?
EW Profitability Score
Profitability Due Diligence
Edwards Lifesciences Corp's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
Score
Edwards Lifesciences Corp's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
EW Solvency Score
Solvency Due Diligence
Edwards Lifesciences Corp's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Score
Edwards Lifesciences Corp's solvency score is 94/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EW Price Targets Summary
Edwards Lifesciences Corp
According to Wall Street analysts, the average 1-year price target for EW is 93.6 USD with a low forecast of 72.72 USD and a high forecast of 110.25 USD.
Ownership
EW Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EW Price
Edwards Lifesciences Corp
Average Annual Return | 9.61% |
Standard Deviation of Annual Returns | 36.74% |
Max Drawdown | -53% |
Market Capitalization | 57.4B USD |
Shares Outstanding | 609 000 000 |
Percentage of Shares Shorted | 1.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,700 full-time employees. The company went IPO on 2000-03-27. The firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. The company also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.
Contact
IPO
Employees
Officers
The intrinsic value of one EW stock under the Base Case scenario is 62.27 USD.
Compared to the current market price of 95.56 USD, Edwards Lifesciences Corp is Overvalued by 35%.